Global Point of Care
BACK
Home > Products

m-PIMA™ HIV-1/2 Viral Load Test

Point-of-Care HIV Viral Load in Less Than 70 Minutes, Not Months

Designed to provide actionable results while the patient is still present.

WHO recommends a viral load test at 6 months and 12 months, and annually thereafter if the patient is stable on ART1, but few patients receive that level of care.

  • UNAIDS 909090 Goal: 90% of patients on ART virally suppressed by 2020, but only 44% actually are.2
  • Approximately 50% of the viral load testing need in low to middle income countries is unmet.2
  • By 2021 low to middle income countries will need an estimated 30 million viral load tests.3

The m-PIMA™ HIV-1/2 VL test is now commercially available in select countries, and has received CE-IVD marking and WHO prequalification. This product is not available in the United States.

Benefits
  • Extend the reach of viral load testing
  • Empower decentralized decision making for better clinical outcomes
  • Empower patients to know their viral load
  • Educate and engage patients on their treatment
  • ART failure, adherence, and switching decisions can be made the same day
  • Reduced sample transport costs
  • Lost samples, lost results, and patients lost to follow up potentially reduced
m-PIMA HIV-1/2 VL
Helpful Documents
  • Lower limit of quantitation: 800 cp/mL for HIV-1 and HIV-2 RNA (below the WHO cut-off value of <1000 cp/mL)
  • Method: Reverse Transcription and Real Time PCR with multiplexing capabilities
  • Time to results: less than 70 minutes
  • Sample volume: 50 μL
  • Sample type: venous EDTA plasma
  • Storage conditions: 4-30°C
  • Connectivity: enabled
m-PIMA™ HIV 1/2 Viral Load Test
 Code
m-PIMA™ Analyser
 27030R001
m-PIMA™ HIV-1/2 VL Cartridge (IVD-CE) 270150050
m-PIMA™ HIV-1/2 VL Cartridge (IVD)
 27015-W50
USB Printer 27040R007
Printer Paper 26040R009
m-PIMA™ HIV Fingerstick Sample Collection Set  270400201

View References

  1. WHO: What’s new in treatment monitoring: viral load and CD4 testing. July 2017
  2. Ending AIDS: progress towards the 90-90-90 targets 2017
  3. Lauren & Biyi, LMIC Forecast Demand for Diagnostic Tests 2016-2021, Avenir Health

Stay informed

Sign up to receive valuable updates from Abbott.

Need Technical Support?

Click here to get in touch with our technical support team.

   

False
accessibility

   

YesNo
accessibility

   

YesNo
accessibility

   

YesNo
accessibility

This website is governed by applicable U.S. laws and governmental regulations. The products and information contained herewith may not be accessible in all countries, and Abbott takes no responsibility for such information which may not comply with local country legal process, regulation, registration and usage. Not all products are available in all regions. Check with your local representative for availability in specific markets. For In Vitro Diagnostic Use Only. For the use of registered medical practitioners, hospitals and Laboratories only.

I understand